

Case Report

Contents lists available at ScienceDirect

Annals of Medicine and Surgery



journal homepage: www.elsevier.com/locate/amsu

# Recurrent giant retroperitoneal liposarcoma: Review of literature and a rare case report

# Lalith Kanthala<sup>\*</sup>, Samrat Ray, Sri Aurobindo Prasad Das, S. Nundy, N. Mehta

Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India

ARTICLE INFO	A B S T R A C T
Keywords: Retroperitoneal liposarcoma De-differentiated Recurrent Surgical excision Case report	Introduction and importance: Retroperitoneal liposarcomas (RPLS) are usually grow large with frequent re- currences. Complete surgical excision remains the gold standard treatment for primary and even recurrent tu- mours. Their prognosis depends on their histological type and grade. We report a recurrent giant de- differentiated RPLS weighing 18.55 kg which was completely excised. To the best of our knowledge, this is one of the largest liposarcoma reported in the literature. <i>Case presentation:</i> A 40 year old female presented with a gradually progressing large abdominal lump for 1year. She had had a similar large lump twice in the past and undergone excision of the tumour elsewhere. Firm non- tender mass felt all over abdomen with edema noted over abdominal wall and bilateral lower limbs. PET CT showed large heterogeneously enhancing mass occupying almost the entire abdominopelvic cavity. $50 \times 40 \times$ 40cm tumour was completely excised and biopsy showed grade 2 dedifferentiated liposarcoma (DDLS). She is under close follow up with no recurrence at 12months. <i>Clinical discussion:</i> DDLS have lower risk of distant metastases but have a high risk of local recurrence. The most important favourable prognostic factor in these tumours is complete resection with negative margins. Because of the ineffectiveness of current chemotherapy and the requirement of intolerably high radiation doses, surgical excision remains the most effective treatment even for the localized recurrences of RPLS. <i>Conclusion:</i> The dedifferentiated subtype should be suspected in locally aggressive RPLS. Close follow up with early detection of recurrences and prompt excision with negative margins lowers the risk of recurrences and improves survival.

# 1. Introduction

This work has been reported as in line with the SCARE 2020 criteria [1]. Retroperitoneal sarcomas account for 10–15% of all soft tissue sarcomas [2]. Among them liposarcomas are the most common (20–45%); others include leiomyosarcomas, malignant fibrous histio-cytomas and undifferentiated pleomorphic sarcomas [2,3]. Retroperitoneal liposarcomas (RPLS) are usually asymptomatic until they grow large enough to produce compression symptoms. Complete surgical excision remains the gold standard treatment for primary and even recurrent tumours as chemotherapy and radiotherapy have a very limited role [4,5]. Histological type and grade, further dictate the prognosis of liposarcomas as dedifferentiated, round cell and pleomorphic types are known for higher rate of recurrence and associated with a poor prognosis [6]. We report the case of a 40 year old female with a

recurrent giant retroperitoneal dedifferentiated liposarcoma weighing 18.55 kg which was completely excised without removing any other abdominal organ. To the best of our knowledge, this is one of the largest liposarcoma reported in the literature. We believe that this case report helps to know more about this rare entity and it will be good for the researchers to review the literature regarding dedifferentiated liposarcoma.

# 2. Case report

A 40 year old female, suffering from hypothyroidism for 6 years, presented to our outpatient department with a gradually progressing large abdominal lump for 1 year associated with bilateral pedal edema and difficulty in breathing for 1 month. She had had a similar large lump in 2013 and 2017, and had twice undergone excision of the tumour

\* Corresponding author.

https://doi.org/10.1016/j.amsu.2021.102329

Received 11 February 2021; Received in revised form 11 April 2021; Accepted 13 April 2021 Available online 17 April 2021

*E-mail addresses:* lalith39@hotmail.com (L. Kanthala), samrat.ray2711@gmail.com (S. Ray), aurobindodas84@gmail.com (S. Aurobindo Prasad Das), snundy@ hotmail.com (S. Nundy), dr.nmehta@hotmail.com (N. Mehta).

<sup>2049-0801/© 2021</sup> Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licensee/by/4.0/).

elsewhere. Biopsy revealed a well differentiated liposarcoma. She received 6 cycles of chemotherapy after the second surgery and her last cycle was in March 2018. She had not had radiotherapy. She was well till November 2018 when she again noticed a lump in the lower abdomen which gradually increased in size occupying her entire abdomen. There were no symptoms suggestive of bowel or urinary bladder involvement and no history of jaundice, back pain or headache.

On examination, she was moderately built and nourished with weight of 83 kg, height of 161 cm and body mass index (BMI) of 32. She had a distended abdomen with a midline scar from a previous laparotomy. Firm non-tender mass felt all over abdomen with edema noted all over abdominal wall and bilateral lower limbs. Her bowel sounds were heard in the left upper quadrant of the abdomen. On digital rectal examination, a mass was felt anteriorly compressing the rectum. Her all lab parameters were within normal limits except for raised thyroidstimulating hormone that was managed by increasing the dose of thyroxin from 25mcg to 50mcg once daily. She was evaluated with a PET CT (Fig. 1) which showed a mildly FDG avid, large heterogeneously enhancing lesion with a predominantly fat component occupying almost the entire abdominopelvic cavity with displacement of the other intraabdominal organs. No other significant FDG avid lesion was seen elsewhere in the body.

As it was a second recurrence of the tumour and the patient refused neo-adjuvant therapy, it was decided to relieve her symptoms by surgical excision. On exploration by a senior consultant in surgical gastroenterology and liver transplantation department in this tertiary care center, a huge  $50 \times 40 \times 40$ cm yellowish encapsulated multilobular retroperitoneal tumour mass was found extending from the diaphragm to the pelvis (Fig. 2). The entire small bowel and right-sided colon were pushed to the left hypochondrium with minimal interloop adhesions. The liver and right kidney were pushed cranially and medially. The tumour was completely excised without removing any other abdominal organ. The total weight of the excised tumor specimen was 18.55kg.

Her post-operative course was uneventful. At the time of discharge, 1 week after surgery, her weight was reduced to 61 kg with BMI of 23.5. The final histopathology report was suggestive of large grade 2, dedifferentiated liposarcoma (DDL) with undifferentiated pleomorphic sarcoma (UPS) features (Fig. 3), with less than 50% necrosis and a mitotic rate of 5–6/10hpf. pT4N0Mx (stage 3B according to AJCC staging system 8th edition). She is now under close follow up with no recurrence detected on a CT scan at 12months.

#### 3. Discussion

Retroperitoneal liposarcomas (RPLS) are rare malignant tumours,

representing between 0.07 and 0.2% of all neoplasms and are the most common sarcomas arising in this region [7]. The average age of presentation is between 40 and 60 years, with an equal sex distribution [8]. They are believed to be sporadic and thought to arise due to genetic abnormalities.

Most of the giant liposarcomas reported in the literature belongs to the dedifferentiated subtype [9,10] as the most common site for them being the retroperitoneum which has a large potential space, allows them to grow very big without being noticed and to become dedifferentiated over a longtime. Dedifferentiation occurs in up to 10% of liposarcomas [11].

A dedifferentiated liposarcoma (DDLS) is defined as a primary or recurrent well-differentiated liposarcoma (WDLS), with a region of abrupt transition to a non-lipogenic sarcoma [6]. Both fatty and nonfatty components are seen in the same tumour on CT or MRI. Macroscopically, they appear as large multinodular yellow masses with distinct tan-to-gray coloured non-lipomatous solid areas, which may contain areas of necrosis or haemorrhage.

DDLS have a lower risk of distant metastases than other high-grade liposarcomas but have a high risk of local recurrence. In a series of 65 primary retroperitoneal DDLS patients, the 3-year recurrence-free survivals observed were 17% for local and 70% for distal recurrences and the 5-year disease-specific survival was only 20% [12]. The most important favourable prognostic factor in these tumours is complete resection with negative margins. According to another series, R0 resection increases survival from 16.7% to 58% with a median survival of 103 months and 18 months in R1 and R2 resections respectively [7,8].

Mortality from RPLS is usually due to local recurrence as a result of incomplete resection. This occurs mostly due to difficulty in differentiating the tumour from adjacent normal fat and due to an inability to obtain a safe margin in the absence of a definite vascular-lymphatic peduncle of the tumour.[13] Recurrence of liposarcoma after initial surgery has been frequently observed within 6 months to 2 years with a rapid growth pattern with the mean tumour volume doubling time of about 100 days.[14].

Because of the ineffectiveness of current chemotherapy and the requirement of intolerably high radiation doses, surgical excision remains the most effective treatment even for the localized recurrences of RPLS. The possibility of complete surgical resection in patients with a first recurrence is up to 80%, however it decreases to 60–70% for the subsequent recurrences [6]. Surgery may be combined with neoadjuvant systemic therapy or intensity modulated radiotherapy depending on the histologic subtype, growth rate, and extent of disease.

All symptomatic local recurrences and asymptomatic recurrences which are impinging on critical structures or suspicious of



Fig. 1. Cross-sectional and coronal CT images of the abdomen: large heterogeneously enhancing mass with a predominantly fat component occupying almost the entire abdominopelvic cavity (large arrows) with cranial displacement of the liver and small bowel in left hypochondrium (small arrows).



Fig. 2. Intra operative images showing huge multilobulated encapsulated lipomatous tumor occupying the entire abdominal cavity.





dedifferentiation on CT scan with a growth rate of less than 1cm per month should be offered surgery. The asymptomatic local recurrences with a growth rate of more than 1 cm per month should be offered systemic chemotherapy or new targeted therapy trials [6].

#### 4. Conclusion

Recurrence after excision of retroperitoneal liposarcomas is common. The dedifferentiated subtype should be suspected in cases which are locally aggressive. Close follow up with CT scans detects early recurrences and prompt reoperation with complete excision with negative margins lowers the risk of recurrences and improves survival.

# **Conflicts of interest**

None declared.

#### Sources of funding

None.

#### **Ethical approval**

Ethical approval was not required.

#### Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

### Author contribution

Lalith Kanthala – Data Collection and analysis, Drafting article. Samrat Ray, Sri Aurobindo Prasad Das – Study conceptualization and designing, Drafting.

Samiran Nundy, Naimish Mehta - Final Drafting.

#### **Research** registration

N/a.

### Guarantor

Dr Lalith Kanthala.

#### Provenance and peer review

Not commissioned, externally peer-reviewed.

# Declaration of competing interest

None.

# Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.

#### org/10.1016/j.amsu.2021.102329.

#### Ethical approval

Not required.

# Sources of funding

None.

# Author contribution

Lalith Kanthala – Data Collection and analysis, Drafting article. Samrat Ray, Sri Aurobindo Prasad Das – Study conceptualization and designing, Drafting.

Samiran Nundy and Naimish Mehta - Final Drafting.

# **Registration of research studies**

Name of the registry: N/a.

Unique Identifying number or registration ID: N/a.

Hyperlink to your specific registration (must be publicly accessible and will be checked):

#### Guarantor

Dr Lalith Kanthala, Senior Resident, Room no.1469, Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi-110060, India. Email: lalith39@hotmail.com.

#### Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

#### References

- R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, for the SCARE Group, The SCARE 2020 guideline: updating consensus surgical CAse REport (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.
- [2] F. Mendoza-Moreno, M.R. Díez-Gago, J. Mínguez-García, D. Enjuto-Martinez, B. Tallón-Iglesias, M. Solana-Maoño, et al., Case report of giant retroperitoneal liposarcoma in a young woman, Int. Surg. J 5 (2018) 2917–2920.
- [3] L.E. Matthyssens, D. Creytens, W.P. Ceelen, Retroperitoneal liposarcoma: current insights in diagnosis and treatment, Front. Surg. 2 (2015) 4.
- [4] D. Caputo, M. Cartillone, G. Spagnolo, S. Lauricella, V. La Vaccara, R. Coppola, Redo surgery for recurrent giant abdominal liposarcoma: description of a case report and literature review, Clin. Surg. 2 (2017) 1376.
- [5] F.X. Moyon, M.A. Moyon, J.F. Tufiño, A. Yu, O.L. Mafla, G.A. Molina, Massive retroperitoneal dedifferentiated liposarcoma in a young patient, J. Surg. Case Rep. (2018) 1–4, 2018.
- [6] V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, eleventh ed., Wolters Kluwer, Philadelphia, PA, 2019, pp. 2489–2550.
- [7] A. Vijay, L. Ram, Retroperitoneal liposarcoma: a comprehensive review, Am. J. Clin. Oncol. 38 (2015) 213–219.
- [8] W.-D. Zhang, D.-R. Liu, R.-S. Que, C.-B. Zhou, C.-N. Zhan, J.-G. Zhao, et al., Management of retroperitoneal liposarcoma: a case report and review of the literature, Oncol. Lett. 10 (2015) 405–409.
- [9] A.M. Eltweri, G. Gravante, S.L. Read-Jones, S. Rai, D.J. Bowrey, I.G. Haynes, A case of recurrent mesocolon myxoid liposarcoma and review of the literature, Case Rep. Oncol. Med. (2013) 1–6, 2013.
- [10] M. Sharma, R. Mannan, T.S. Bhasin, M. Manjari, R. Punj, Giant inflammatory variant of well differentiated liposarcoma: a case report of a rare entity, J. Clin. Diagn. Res. 7 (2013) 1720–1721.
- [11] K. Thway, R.L. Jones, J. Noujaim, S. Zaidi, A.B. Miah, C. Fisher, Dedifferentiated liposarcoma: updates on morphology, genetics, and therapeutic strategies, Adv. Anat. Pathol. 23 (2016) 30–40.
- [12] S. Singer, C.R. Antonescu, E. Riedel, M.F. Brennan, Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma, Ann. Surg. 238 (2003) 358–371.
- [13] P.H.A. Nijhuis, P.R.A. Sars, B.E.C. Plaat, W.M. Molenaar, W.J. Sluiter, H. J. Hoekstra, Clinico-pathological data and prognostic factors in completely resected AJCC stage I-III liposarcomas, Ann. Surg Oncol. 7 (2000) 535–543.
- [14] W.W. Tseng, J.E. Madewell, W. Wei, N. Somaiah, A.J. Lazar, M.P. Ghadimi, et al., Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann. Surg Oncol. 21 (2014) 2136–2143.